Sound Surgical Technologies, LLC, Louisville, CO, USA.
Aesthet Surg J. 2013 Jul;33(5):698-704. doi: 10.1177/1090820X13485239. Epub 2013 May 29.
Although clinical evidence of successful autologous fat transfer (AFT) using third-generation ultrasound-assisted liposuction (UAL) is readily available, no study has quantified adipocyte viability using standardized methods.
The authors assess acute adipocyte viability following fat aspiration as a first step in determining the overall efficacy of using third-generation UAL for AFT.
Lipoaspirate samples were collected from patients who underwent elective liposuction procedures at multiple surgery centers. Patients with a history of bleeding disorders, diabetes, human immunodeficiency virus, or lipoatrophy disorders were excluded. The UAL system (VASER; Sound Surgical Technologies, Inc, Louisville, Colorado) was set at 60% amplitude in pulsed mode with vacuum aspiration of 15 in Hg or less. Laboratory analysis included free lipid volume, viability via lipolysis and propidium iodide staining, and cytological analysis, including cell surface protein examination and hematoxylin and eosin staining.
The lipolysis assay revealed metabolically active adipocytes with a mean (SD) correlative viability of 85.1% (11%). Direct measures of acute viability via propidium iodide staining resulted in a mean (SD) viability measure of 88.7% (3.5%). Both mean values are within the historical range reported from syringe and vacuum-assisted lipoaspiration. Aqueous and lipid contents were favorably reduced after washing and filtering (Puregraft system; Cytori Therapeutics, Inc, San Diego, California). Cellular phenotypes identified were primarily white blood cells or vascular endothelial and vascular associated cells.
Adipose tissue acquired via third-generation UAL is viable at harvest and is potentially a suitable source for autologous fat grafts. These results confirm reported clinical successes utilizing third-generation ultrasound lipoaspirate for AFT.
尽管使用第三代超声辅助吸脂术(UAL)进行自体脂肪移植(AFT)的临床成功证据已经很充分,但尚无研究使用标准化方法定量评估脂肪细胞的存活率。
作者评估脂肪抽吸后脂肪细胞的急性存活率,作为确定第三代 UAL 用于 AFT 的总体疗效的第一步。
从多个手术中心接受择期吸脂术的患者中收集脂肪抽吸样本。排除有出血性疾病、糖尿病、人类免疫缺陷病毒或脂肪萎缩性疾病病史的患者。UAL 系统(VASER;声外科技术公司,科罗拉多州路易斯维尔)以 60%的振幅设置在脉冲模式下,真空抽吸小于 15 英寸汞柱。实验室分析包括游离脂质体积、通过脂肪分解和碘化丙啶染色评估的存活率,以及细胞学分析,包括细胞表面蛋白检查和苏木精-伊红染色。
脂肪分解测定法显示代谢活跃的脂肪细胞,平均(SD)相关存活率为 85.1%(11%)。通过碘化丙啶染色直接测量急性存活率,得出平均(SD)存活率为 88.7%(3.5%)。这两个平均值都在从注射器和真空辅助吸脂术报告的历史范围内。洗涤和过滤后(Puregraft 系统;Cytori Therapeutics,Inc,圣地亚哥,加利福尼亚州),水相和脂质含量都得到了有利的降低。鉴定的细胞表型主要是白细胞或血管内皮和血管相关细胞。
通过第三代 UAL 获得的脂肪组织在收获时是有活力的,并且可能是自体脂肪移植的合适来源。这些结果证实了利用第三代超声吸脂术进行 AFT 的报道的临床成功。